Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEFADYL (cephapirin sodium) is an injectable first-generation cephalosporin antibiotic used to treat bacterial infections in hospitalized patients. It is administered intravenously or intramuscularly and works by inhibiting bacterial cell wall synthesis. The product is currently in pre-launch stage under Bristol Myers Squibb sponsorship.
Pre-Launch
Early-stage asset with undefined commercial potential; team composition and size contingent on regulatory and clinical outcomes.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CEFADYL during pre-launch offers exposure to product development and hospital formulary strategy in the antibiotic space. Career growth depends heavily on successful regulatory approval and commercial execution in a commoditized market segment.
Brand ManagerProduct Manager
Worked on CEFADYL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.